KalVista Pharmaceuticals Inc has terminated a mid-stage trial of its prophylactic drug candidate for hereditary angioedema (HAE) following safety issues but is holding out hope for a more advanced on-demand program for the rare disease.
Kalvista Stops Phase II HAE Prophylactic Trial Following Liver Enzyme Concerns
But On-Demand Asset On Track
The US firm’s oral plasma kallikrein inhibitor was associated with liver elevations in a number of Phase II patients, prompting a trial termination and shift in focus to an on-demand program.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.